Biology Reference
In-Depth Information
[24] Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M. Type I inter-
feron negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med
2011;208(12):2367-74.
[25] Hwang SY, Hertzog PJ, Holland KA, Sumarsono SH, Tymms MJ, Hamilton JA, et al. A
null mutation in the gene encoding a type I interferon receptor component eliminates
antiproliferative and antiviral responses to interferons alpha and beta and alters mac-
rophage responses. Proc Natl Acad Sci U S A 1995;92(24):11284-8.
[26] Webb IJ, Eickhoff CE, Elias AD, Ayash LJ, Wheeler CA, Schwartz GN, et al. Kinetics of
peripheral blood mononuclear cell mobilization with chemotherapy and/or granulo-
cyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell
collections. Transfusion 1996;36(2):160-7.
[27] Robb RJ, Kreijveld E, Kuns RD, Wilson YA, Olver SD, Don AL, et al. Type I-IFNs control
GVHD and GVL responses after transplantation. Blood 2011;118(12):3399-409.
[28] Klingemann HG, Grigg AP, Wilkie-Boyd K, Barnett MJ, Eaves AC, Reece DE, et al. Treat-
ment with recombinant interferon (alpha-2b) early after bone marrow transplantation
in patients at high risk for relapse [corrected]. Blood 1991;78(12):3306-11.
[29] Steegmann JL, Casado LF, Tomas JF, Sanz-Rodriguez C, Granados E, de la Camara R,
et al. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone
marrow transplantation. Bone Marrow Transplant 1999;23(5):483-8.
[30] Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, et al. Effect of
prior interferon alfa therapy on the outcome of allogeneic bone marrow transplanta-
tion for chronic myelogenous leukemia. J Clin Oncol 1993;11(6):1055-61.
[31] O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Ima-
tinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-
phase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004.
[32] Simonsson B, Gedde-Dahl T, Markevärn B, Remes K, Stentoft J, Almqvist A, et al.
Combination of pegylated IFN-α2b with imatinib increases molecular response
rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood
2011;118(12):3228-35.
[33] Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive,
quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leuke-
mia are insensitive to STI571 in vitro. Blood 2002;99(1):319-25.
[34] Burchert A, Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D, et al. Interferon-α, but not
the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a
specific T-cell response in chronic myeloid leukemia. Blood 2003;101(1):259-64.
[35] Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, et al. Differential roles
of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin
Invest 1999;104(4):459-67.
[36] Hill GR, Teshima T, Rebel VI, Krijanovski OI, Cooke KR, Brinson YS, et al. The p55 TNF-
alpha receptor plays a critical role in T cell alloreactivity. J Immunol 2000;164(2):656-63.
[37] Markey KA, Burman AC, Banovic T, Kuns RD, Raffelt NC, Rowe V, et al. Soluble lympho-
toxin is an important effector molecule in GVHD and GVL. Blood 2010;115(1):122-32.
[38] Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, et al. Donor T
cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activ-
ity after bone marrow transplantation. Blood 2003;101(6):2440-5.
[39] Hill GR, Cooke KR, Brinson YS, Bungard D, Ferrara JL. Pretransplant chemotherapy
reduces inflammatory cytokine production and acute graft-versus-host disease after
allogeneic bone marrow transplantation. Transplantation 1999;67(11):1478-80.
[40] Ewing P, Miklos S, Olkiewicz KM, Muller G, Andreesen R, Holler E, et al. Donor CD4+
T-cell production of tumor necrosis factor alpha significantly contributes to the early
proinflammatory events of graft-versus-host disease. Exp Hematol 2007;35(1):155-63.
[41] Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metallo-
proteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature
1997;385(6618):729-33.
[42] Gommerman JL, Browning JL. Lymphotoxin/light, lymphoid microenvironments and
autoimmune disease. Nat Rev Immunol 2003;3(8):642-55.
[43] Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways acti-
vated by TNF superfamily. Cytokine Growth Factor Rev 2003;14(3-4):193-209.
[44] Bigda J, Beletsky I, Brakebusch C, Varfolomeev Y, Engelmann H, Bigda J, et al. The dual
role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J Exp Med
1994;180:445.
[45] Williams TW, Granger GA. Lymphocyte in vitro cytotoxicity: lymphotoxins of several
mammalian species. Nature 1968;219(5158):1076-7.
[46] Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members
of the TNF superfamily. Biochem Pharmacol 2003;66(8):1403-8.
383
Search WWH ::
Custom Search